Novartis agreed to acquire Excellergy in a deal valued at up to $2 billion, bringing a next-generation anti-IgE program into the Swiss pharma’s allergy portfolio. Excellergy’s lead, Exl-111, is an effector cell response inhibitor (ECRI) that aims to suppress IgE signaling while avoiding triggering activation of mast cells and basophils. The deal follows Excellergy’s launch just months after a $70 million Series A, and the lead asset has entered Phase I clinical testing. Novartis framed Exl-111 as a potential Xolair successor strategy as competition intensifies, and emphasized faster and deeper IgE pathway suppression based on preclinical work and early pharmacokinetic data. For the broader immunology deal pipeline, the transaction is a reminder that platform-driven immunology startups can still attract large-ticket acquirers even at early clinical stages when differentiation and mechanism are clear.